TGFB1 and neoplasm: CMS4 has the worst prognosis out of the four subtypes of CRC, and therapy that targets CMS4-like TGF-β-activated CRC paves the route for overcoming the tumor microenvironmental interaction that promotes the mesenchymal phenotype.